- Home
- NITO vs XOMAP Comparison
NITO vs XOMAP Comparison
Compare NITO & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NITO
- XOMAP
- Stock Information
- Founded
- NITO 2009
- XOMAP N/A
- Country
- NITO Israel
- XOMAP United States
- Employees
- NITO 5
- XOMAP 13
- Industry
- NITO
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- NITO
- XOMAP Health Care
- Exchange
- NITO NYSE
- XOMAP Nasdaq
- Market Cap
- NITO 4.2M
- XOMAP N/A
- IPO Year
- NITO N/A
- XOMAP N/A
- Fundamental
- Price
- NITO $0.42
- XOMAP $25.49
- Analyst Decision
- NITO
- XOMAP
- Analyst Count
- NITO 0
- XOMAP 0
- Target Price
- NITO N/A
- XOMAP N/A
- AVG Volume (30 Days)
- NITO 37.0M
- XOMAP N/A
- Earning Date
- NITO 05-19-2025
- XOMAP N/A
- Dividend Yield
- NITO N/A
- XOMAP N/A
- EPS Growth
- NITO N/A
- XOMAP N/A
- EPS
- NITO N/A
- XOMAP N/A
- Revenue
- NITO $210,000.00
- XOMAP N/A
- Revenue This Year
- NITO N/A
- XOMAP N/A
- Revenue Next Year
- NITO N/A
- XOMAP N/A
- P/E Ratio
- NITO N/A
- XOMAP N/A
- Revenue Growth
- NITO N/A
- XOMAP N/A
- 52 Week Low
- NITO $0.16
- XOMAP N/A
- 52 Week High
- NITO $3.49
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- NITO 57.56
- XOMAP 45.51
- Support Level
- NITO $0.30
- XOMAP $25.21
- Resistance Level
- NITO $0.84
- XOMAP $26.28
- Average True Range (ATR)
- NITO 0.09
- XOMAP 0.17
- MACD
- NITO 0.03
- XOMAP -0.04
- Stochastic Oscillator
- NITO 34.92
- XOMAP 31.78
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.